3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Interventions
plerixafor
1
pazopanib
1
lorukafusp alfa
1
liposomal doxorubicin
1
imetelstat
1
Temozolomide
1
Pentetic Acid
1
Palliative Care
1
Nutritional Support
1
Minocycline
1
MAGEA3 protein, human
1
MAGEA1 protein, human
1
Heparin
1
Glutamine
1
Gemcitabine
1
GRN163L peptide
1
Filgrastim
1
Erlotinib Hydrochloride
1
Electroacupuncture
1
Docetaxel
1
Dexamethasone
1
Celecoxib
1
Calcium Carbonate
1
Analgesia
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Osteosarcoma
×
MAGEA3 protein, human
×
Clear all
NCT00944580
2017-11-24
A Vaccine Study for High Risk Cancers
Penn State University
Phase 1
Withdrawn